New Therapeutic Targets for Drug Design Against Trypanosoma cruzi, Advances and Perspectives
Abstract:Chagas disease is one of the most important parasitic diseases in Latin America, affecting16 to 18 million people. Nifurtimox and Benznidazol are drugs that are commonly used in its treatment; however, these drugs produce several adverse reactions and are not effective in the chronic phase of the disease. Therefore, the design, synthesis, and biological evaluation of new compounds with potential activity against Trypanozoma cruzi are of great importance.
We review six proteins involved in the biochemical metabolism of Trypanosoma cruzi that have recently been studied as potential targets for designing new drugs for Chagas disease. These are farnesyl pyrophosphate synthase, trans-sialidase, cruzain cystein protease, trypanothione reductase, glucose 6-phosphate-dehydrogenase, glyceraldehyde 3-phosphatedehydrogenase, and α-hydroxy acid dehydrogenase. We also review the advances of compounds recently designed based on structure-activity, and the perspectives of new compounds that inhibit these therapeutic targets.
Document Type: Research Article
Affiliations: Departamento de Biologia Molecular y Bioingenieria, Unidad Academica Multidisciplinaria Reynosa- Aztlan, Universidad Autonoma de Tamaulipas, Calle 16 y Lago de Chapala, s/n, Reynosa, Tamaulipas, 88740, Mexico.
Publication date: September 1, 2009
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.